| 70.64 -0.34 (-0.48%) | 02-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 90.06 | 1-year : | 96.03 |
| Resists | First : | 77.11 | Second : | 82.22 |
| Pivot price | 76.83  |
|||
| Supports | First : | 68.84 | Second : | 57.28 |
| MAs | MA(5) : | 73.47 |
MA(20) : | 75.52  |
| MA(100) : | 69.65 |
MA(250) : | 64.84 |
|
| MACD | MACD : | 0.4 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 7.1 |
D(3) : | 20.5 |
| RSI | RSI(14): 41.1 |
|||
| 52-week | High : | 82.22 | Low : | 47.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ HALO ] has closed above bottom band by 6.5%. Bollinger Bands are 46.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 71.43 - 71.93 | 71.93 - 72.31 |
| Low: | 68.49 - 69.17 | 69.17 - 69.69 |
| Close: | 69.7 - 70.62 | 70.62 - 71.33 |
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Mon, 23 Feb 2026
Halozyme Therapeutics (HALO) Stock Analysis: Strong Revenue Growth and Significant Upside Potential - DirectorsTalk Interviews
Thu, 19 Feb 2026
Wells Fargo Raises Price Target on Halozyme Therapeutics (HALO) to $75 | HALO Stock News - GuruFocus
Thu, 19 Feb 2026
Halozyme (HALO) Loses 9% on Weak Earnings - Yahoo Finance
Thu, 19 Feb 2026
Halozyme Therapeutics (HALO) Q4 Loss On US$451.8m Revenue Tests ENHANZE Profit Narrative - simplywall.st
Wed, 18 Feb 2026
Why Halozyme Therapeutics (HALO) Is Down 7.9% After Acquisition-Driven Q4 Loss And 2026 Outlook Reaffirmation - Yahoo Finance
Wed, 18 Feb 2026
Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge (NASDAQ:HALO) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 118 (M) |
| Shares Float | 117 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 107.5 (%) |
| Shares Short | 13,520 (K) |
| Shares Short P.Month | 13,800 (K) |
| EPS | 4.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 22.6 % |
| Operating Margin | 56.3 % |
| Return on Assets (ttm) | 22.2 % |
| Return on Equity (ttm) | 153.5 % |
| Qtrly Rev. Growth | 51.5 % |
| Gross Profit (p.s.) | 9.26 |
| Sales Per Share | 11.9 |
| EBITDA (p.s.) | 7.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 652 (M) |
| Levered Free Cash Flow | 185 (M) |
| PE Ratio | 14.9 |
| PEG Ratio | 0 |
| Price to Book value | 172.29 |
| Price to Sales | 5.93 |
| Price to Cash Flow | 12.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|